All In Biotech

Drug Trial Radar · NCT06702553

Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass

Effect of Inhaled Nitric Oxide on Major Adverse Events Requiring Intensive Life Support in Adults Undergoing Cardiac Surgery With Cardiopulmonary Bypass: A Phase III, Double-Blind, Multicenter, Randomized Controlled Trial (Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass, the NORISC Trial)

Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 3,650 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,650

Planned (sponsor's estimate)

Start

May 19, 2025

Primary completion

Mar 31, 2028

Study completion Mar 31, 2029

Sponsor

Lead sponsor
Xijing HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Nikolay O. Kamenshchikov., M.D., Tomsk National Research Medical Center of the Russian Academy of Sciences; Lorenzo Berra., M.D., Massachusetts General Hospital; Tianjin Chest Hospital; Qingping Wu, Wuhan Union Hospital, Wuhan, China; Evgeniy Grigoriev, Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation; Vladimir Boboshko, E. Meshalkin National Medical Research Center, Novosibirsk, Russian Federation; Andrei Bautin, The Almazov National Medical Research Centre, St. Petersburg, Russian Federation; Vladimir Pichugin, Specialized Cardiac Surgery Clinical Hospital named after Academician B.A. Korolev, Nizhny Novgorod, Russian Federation; Evgeniy Rosseykin, Federal Center of Cardiovascular Surgery, Khabarovsk, Russian Federation; Jing Shi, The Afffliated Hospital of Guizhou Medical University, Guiyang, China.; Grigoryev Evgeny, Scientific Research Insitute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia.; Mikhail Vasilev, Meshalkin National Medical Research Center, Мeshalkin of the ministry of health of the Russian Federation,Novosibirsk,Russia.; The First Affiliated Hospital of Nanchang University; Jiawan Wang, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China; Zongbin Song, Xiangya Hospital, Central South University, Changsha, China.
First posted
Nov 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cardiac surgery is a procedure that is commonly performed worldwide. Despite these technological advances, cardiac surgery remains a high-risk surgery. Among post-operative complications, acute kidney injury, respiratory failure, myocardial infarction, and stroke as well as cognitive dysfunction are significant causes of mortality in patients undergoing and following cardiac surgery. Inhaled nitric oxide (NO) therapy as a selective pulmonary vasodilator in cardiac surgery has been one of the most significant pharmacological advances in managing pulmonary hemodynamics and life threatening right ventricular dysfunction and failure. In addition, newer applications show greater promise of inhaled NO as a therapy in the area of cardiac surgery associated acute kidney injury and ischemia reperfusion. However, this remarkable expectation to inhaled NO has experienced a roller-coaster ride with high hopes and nearly universal demonstration of physiological benefits but disappointing translation of these benefits to harder clinical outcomes, like mortality. Most of our understanding on the iNO field in cardiac surgery stems from small observational or single center randomized trials, which failed to ascertain strong evidence base. As a consequence, there are only week clinical practice guidelines on the field and only European expert opinion for the use of iNO in routine and more specialized cardiac surgery. There is need for a large multicenter randomized controlled study to confirm the administration of iNO as an effective weapon for the battle against life threatening complication in high risk cardiac surgical patients. In a previous meta analysis with 27 studies included, we demonstrated that inhaled nitric oxide (NO) could reduce the duration of mechanical ventilation and reducing biomarkers of organ injury and clinical signs of organ dysfunction in cardiac surgery under cardiopulmonary bypass (CPB) , but had no significance in the ICU stay, hospital stay, and mortality. This may be attributed to the small sample size of the most included studies (of the 27 studies included, 20 studies with sample size less than 100) and heterogeneity in timing, dosage and duration of iNO administration. Well-designed, large-scale, multicenter clinical trials are needed to further explore the effect of iNO in improving postoperative prognosis in cardiovascular surgical patients. We are planning a large multicenter controlled randomized trial to demonstrate that inhaled nitric oxide can reduce composite outcome of death and Major Adverse Events (MAEs), including need for intensive supports due to heart failure, low cardiac output sydrome, or renal failure, respiratory failure, etc., and myocardial infarction, stroke, and sepsis at 30 days after surgery from 20% to 16% in patient undergoing cardiac surgery with cardiopulmonary bypass. If the hypothesis had been proved and validated, the results of this study can provide strong evidence for guidelines to facilitate the routine use of iNO in all cardiopulmonary bypass assisted cardiac procedures with 31,800 postoperative outcomes improved per year in US and in China.

Conditions

  • Nitric Oxide
  • Cardiac Surgery
  • Cardiopulmonary Bypass
  • Adult Patients Undergoing Cardiovascular Surgery With Cardiopulmonary Bypass

Interventions

  • Nitric Oxide GasDrug

    Patients will receive 80 parts per million (ppm) NO during CPB through the oxygenator. After weaning of CPB, test gases will be delivered via inspiration limb of ventilator at a dose range of 40-80 ppm until 6 hours after ICU admission or until extubation after surgery, whichever comes first.

  • Standard Care ArmDrug

    Patients in this group will receive standard care and 80 ppm nitrogen (N2, control group) are added to the gas mixture as control. In the circumstances when the N2 is not applicable, such as when the plasma-chemical NO synthesis device is employed for NO generatiaon and delivery, the device will be connected to the CPB and ventilator circuits, but the synthesis will remain inactive in the control group. Consequently, the circuit will be supplied with air devoid of NO.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite outcome of death and major adverse events requiring intensive life supportsTime frame: within 30 days after operation

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • Massachusetts General Hospital, Department of Anesthesia, Critical Care and Pain Medicine

    Boston, Massachusetts · Not yet recruiting

  • Xijing Hospital

    Xi'an, Shaanxi, China · Recruiting

  • Cardiology Research Institute, Tomsk National Research Medical Center

    Tomsk, Russia · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.